Casi Pharmaceuticals Stock Market Value
| CASI Stock | USD 0.78 0.04 4.88% |
| Symbol | CASI |
Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
CASI Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CASI Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CASI Pharmaceuticals.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in CASI Pharmaceuticals on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding CASI Pharmaceuticals or generate 0.0% return on investment in CASI Pharmaceuticals over 90 days. CASI Pharmaceuticals is related to or competes with Cingulate, Curis, Pelthos Therapeutics, NuCana PLC, Palisade Bio, Allarity Therapeutics, and Kairos Pharma. CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical pro... More
CASI Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CASI Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CASI Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 35.41 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 11.84 |
CASI Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CASI Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CASI Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use CASI Pharmaceuticals historical prices to predict the future CASI Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.83) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (1.04) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CASI Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CASI Pharmaceuticals February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (1.03) | |||
| Mean Deviation | 3.82 | |||
| Coefficient Of Variation | (711.86) | |||
| Standard Deviation | 5.6 | |||
| Variance | 31.41 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.83) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (1.04) | |||
| Maximum Drawdown | 35.41 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 11.84 | |||
| Skewness | 1.73 | |||
| Kurtosis | 5.99 |
CASI Pharmaceuticals Backtested Returns
CASI Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0956, which signifies that the company had a -0.0956 % return per unit of volatility over the last 3 months. CASI Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CASI Pharmaceuticals' Variance of 31.41, mean deviation of 3.82, and Market Risk Adjusted Performance of (1.03) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.77, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CASI Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding CASI Pharmaceuticals is expected to be smaller as well. At this point, CASI Pharmaceuticals has a negative expected return of -0.55%. Please make sure to confirm CASI Pharmaceuticals' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if CASI Pharmaceuticals performance from the past will be repeated in the future.
Auto-correlation | 0.14 |
Insignificant predictability
CASI Pharmaceuticals has insignificant predictability. Overlapping area represents the amount of predictability between CASI Pharmaceuticals time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CASI Pharmaceuticals price movement. The serial correlation of 0.14 indicates that less than 14.0% of current CASI Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.14 | |
| Spearman Rank Test | 0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out CASI Pharmaceuticals Correlation, CASI Pharmaceuticals Volatility and CASI Pharmaceuticals Performance module to complement your research on CASI Pharmaceuticals. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
CASI Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.